Clinical implications of neuroendocrine differentiation in prostate cancer. - Wikidata - awgldk - TriplyDB

Clinical implications of neuroendocrine differentiation in prostate cancer.

Clinical implications of neuroendocrine differentiation in prostate cancer.

http://www.wikidata.org/entity/Q36639877

about

Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2 Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression.Phenotype-specific CpG island methylation events in a murine model of prostate cancer.Oct4A is expressed by a subpopulation of prostate neuroendocrine cells.The steroid receptor coactivator-3 is required for developing neuroendocrine tumor in the mouse prostate Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine?Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.Prostate cancer with neuroendocrine differentiation--case report Inhibition of Akt pathways in the treatment of prostate cancer.Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling.Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.Recent developments in prostate cancer biomarker research: therapeutic implications.Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review.Biopsy sampling and histopathological markers for diagnosis of prostate cancer.IGFBP3 and MAPK/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer.Characterization of reactive stroma in prostate cancer: involvement of growth factors, metalloproteinase matrix, sexual hormones receptors and prostatic stem cells.SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer.Targeting CREB inhibits radiation-induced neuroendocrine differentiation and increases radiation-induced cell death in prostate cancer cells.Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up-regulation of IRF1.Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer.Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer

P2860

Q24614665-B01CB1AA-99B8-45D5-812E-34A5B8081A68 Q26859201-9822AD0A-4160-41DA-921B-2E0C8059560C Q30432236-E531394D-817F-4DC2-A5BE-5CC58CF893A8 Q33775468-2806C2C4-4650-4CCD-A9DE-3C1B320C4A20 Q33832001-9D9D374A-344E-443A-9B14-CD12D2A166A6 Q34365187-B4E2F3CE-BF9B-4DF7-BED9-B0E9114A7228 Q35141115-E523567C-F249-4F8A-A60B-DFD526E5222C Q35380936-E54D5FE8-C92B-47E8-B26D-896FF7B0D174 Q35423247-DC271F63-56AC-482E-A6FB-4891D670EC85 Q35838308-11C6E9D6-AEA1-42FE-9EF7-F06CB5D023B8 Q36807494-270BA122-1B5C-4E1F-8BFD-2DFE437879BB Q36897348-327CD216-66CC-4EFA-A65A-F82427E89F18 Q37606662-C8675F6D-CB72-43EC-B2FE-3E419D43B7CA Q37705831-FC1ED3A0-172D-4C67-98C5-3B64754501B8 Q37827186-517FAB8A-8A08-41C2-818E-48305CA6284A Q37898112-FC8662B0-F34C-42E4-9BDE-FDAE5EC86259 Q38090427-0AFD15DB-A24D-4C03-BBC5-44A83039F7BB Q38209356-B01C03DC-DAC9-4B61-AE3E-D8FDC16321FC Q38256309-43B4893F-47D9-4A59-83F6-C6A8BB4388B8 Q38290653-11E3D6BF-2B94-4BA8-98FD-1318D22CA7F6 Q38532446-B84F2C6E-9085-4048-8DEC-5E950A2D75AF Q42188512-0453FAAC-6B5A-404D-B56C-2F8C935CF3A9 Q42593140-52219666-9CE4-4F6C-9E56-93712C051A25 Q42650664-86784D76-DDF1-4870-9B73-ED6175A86728 Q47805023-9D14CBC3-D96C-4757-9CFF-BCC573D78FDD Q48125169-42159DD0-4D5C-443C-9EF2-D0D673B80553 Q58327426-DBCA0C03-B04D-4E2B-9FEA-F43023F0A8CF

P2860

Clinical implications of neuroendocrine differentiation in prostate cancer.

http://www.wikidata.org/entity/Q36639877

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Clinical implications of neuroendocrine differentiation in prostate cancer.

@ast

Clinical implications of neuroendocrine differentiation in prostate cancer.

@en

type

label

Clinical implications of neuroendocrine differentiation in prostate cancer.

@ast

Clinical implications of neuroendocrine differentiation in prostate cancer.

@en

prefLabel

Clinical implications of neuroendocrine differentiation in prostate cancer.

@ast

Clinical implications of neuroendocrine differentiation in prostate cancer.

@en

P1433

Q36639877-02CABC19-DE25-4B57-B3BE-593BBF1D3FC6

P1476

Q36639877-336ACF25-4D46-4F04-9705-82A4942E0AC5

P2093

Q36639877-20FCC6B2-0919-4D09-B91E-AE6AE8773207

Q36639877-2416BC1E-352C-4130-9416-C1340CE6713D

Q36639877-645BA8D8-93BA-4D62-9308-5F17D0151E02

Q36639877-7B8C3FC4-2D9E-4503-8B75-23D9E1799D98

Q36639877-AFFBA827-7727-41C8-BD0A-21303EA7E392

Q36639877-F87ADFAC-1C43-4A49-9D57-482D0E56CFD1

P2860

Q36639877-02A6746B-65D0-4943-9E18-28FFE18DC362

Q36639877-0A5996A9-E551-4012-8A8E-A6AD3F990904

Q36639877-0E89487E-A5D5-44CF-B1E6-23E5C4301693

Q36639877-167434DE-14D4-42F2-BCA9-850F26CEC0DA

Q36639877-1865C652-CADD-4C61-90F4-4B2C53372018

Q36639877-1A2154F0-9849-4FB6-84BC-55EF4E3EDB36

Q36639877-22023B2A-66E1-4E80-B825-E9A9B252E6E8

Q36639877-2AA9683D-E7F9-454A-9B4E-D57CF4AAD778

Q36639877-2DC060EB-B5ED-4BEA-A94C-4F12588E6058

Q36639877-2F3B4222-039C-4AC9-8F73-D59506B79CD1

P2888

Q36639877-A4DC8446-B438-4931-A843-C2F9C5DDA807

P304

Q36639877-2B5E3A98-751D-4C5B-A150-25237D284754

P31

Q36639877-B06CDFE7-A549-433E-9FED-B616777FB7A6

P356

Q36639877-B2901EA2-D3ED-42CD-A1EE-EF7B19A82E47

P433

Q36639877-43477E12-DFA3-4089-88B0-8C6806638015

P478

Q36639877-E2052DF7-6C57-4B5B-8677-95A36E140FE2

P577

Q36639877-86C68A0E-331F-4499-8C29-BC825C0CBAA0

P5875

Q36639877-DDD7781C-C071-49E8-9E38-9F8ABC6DF9A5

P698

Q36639877-1A285514-6FDF-4028-A248-B7CC2559B98B

P356

SJ.PCAN.4500922

P1433

Prostate Cancer and Prostatic Diseases

P1476

Clinical implications of neuroendocrine differentiation in prostate cancer.

@en

P2093

Cambio AJ

http://www.w3.org/2001/XMLSchema#string

Evans CP

http://www.w3.org/2001/XMLSchema#string

Lara PN Jr

http://www.w3.org/2001/XMLSchema#string

Nelson EC

http://www.w3.org/2001/XMLSchema#string

Ok JH

http://www.w3.org/2001/XMLSchema#string

Yang JC

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase

Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways

Cancer statistics, 2006

The development of androgen-independent prostate cancer

Neuropeptides bombesin and calcitonin inhibit apoptosis-related elemental changes in prostate carcinoma cell lines.

Regulation of tyrosine kinase cascades by G-protein-coupled receptors.

Neuroendocrine differentiation in prostatic carcinoma.

P2888

sj.pcan.4500922

P304

6-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.PCAN.4500922

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6720125

http://www.w3.org/2001/XMLSchema#string

P698

17075603

http://www.w3.org/2001/XMLSchema#string